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ABSTRACT
The androgen receptor (AR) plays a pivotal role in
the onset and progression of prostate cancer by
promoting cellular proliferation. Recent studies sug-
gest AR is a master regulator of G1-S progression
and possibly a licensing factor for DNA replication
yet the mechanisms remain poorly defined. Here
we report that AR targets the human Cdc6 gene
for transcriptional regulation. Cdc6 is an essential
regulator of DNA replication in eukaryotic cells and
its mRNA expression is inversely modulated by
androgen or antiandrogen treatment in androgen-
sensitive prostate cancer cells. AR binds at a dis-
tinct androgen-response element (ARE) in the Cdc6
promoter that is functionally required for androgen-
dependent Cdc6 transcription. We found that peak
AR occupancy at the novel ARE occurs during the
G1/S phase concomitant with peak Cdc6 mRNA
expression. We also identified several of the coacti-
vators and corepressors involved in AR-dependent
Cdc6 transcriptional regulation in vivo and further
characterized ligand-induced alterations in histone
acetylation and methylation at the Cdc6 promoter.
Significantly, AR silencing in prostate cancer cells
markedly decreases Cdc6 expression and andro-
gen-dependent cellular proliferation. Collectively,
our results suggest that Cdc6 is a key regulatory
target for AR and provide new insights into the
mechanisms of prostate cancer cell proliferation.
INTRODUCTION
Androgens are steroid hormones responsible for the devel-
opment and functional maintenance of male reproductive
and accessory sex tissues. They exert their physiologic
actions by binding to the androgen receptor (AR),
a 110-kDa member of the nuclear receptor family of
ligand-activated transcription factors (1). AR mediates
androgen action by binding to speciﬁc DNA sequences
termed androgen response elements (ARE) found within
promoter or enhancer regions of AR-target genes (2–5).
When bound with androgen, AR can activate target gene
transcription by recruiting distinct coregulatory factors
including enzymes that covalently modify histones and
remodel chromatin (6,7), as well as the Mediator complex
that directly interfaces with the RNA polymerase II (RNA
pol II) basal machinery (8,9). When bound with antian-
drogenic compounds, AR can repress target gene tran-
scription by recruiting negative coregulatory factors
termed corepressors (6,7). Although numerous AR coac-
tivators and corepressors have been reported and charac-
terized, many of the genes directly bound and regulated by
AR in vivo remain poorly deﬁned.
Signiﬁcantly, AR plays a pivotal role in the onset and
progression of prostate cancer by promoting the growth
and proliferation of prostate cancer cells (1,10,11).
Mechanistic investigations have revealed that AR acts
as a master regulator of G1-S phase progression in
androgen-dependent prostate cancer cells (12) and that
AR protein is degraded at mitosis during each cell cycle
(13). These ﬁndings suggest that AR may be acting as a
licensing factor for DNA replication in androgen-sensitive
prostate cancer cells, and that mitotic AR degradation
is required to license a new round of DNA replication.
Treatment options for prostate cancer include androgen-
ablation therapy that initially triggers apoptosis or
cell-cycle arrest of prostate cancer cells (14–16).
Paradoxically, nearly all invasive or metastatic prostate
cancers eventually progress into a fatal androgen-indepen-
dent disease, yet most of these cancers continue to express
AR and remain dependent on AR for growth and survival
(1,10,11). Therefore, identifying the speciﬁc genes regu-
lated by AR will be critical for understanding the mecha-
nisms of androgen-dependent and -independent prostate
cancer cell growth and proliferation.
Cdc6 is an essential regulator of DNA replication in
eukaryotic cells (17). Along with a subset of other key
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complex at the origins of DNA replication early in G1
phase thereby ‘licensing’ these sites to bind DNA polymer-
ase and initiate DNA replication during S phase (18,19).
The expression and functional activity of Cdc6 is tightly
regulated in a cell-cycle-dependent manner thus ensuring
that the entire genome is replicated only once in each cell
division. Indeed, Cdc6 is considered an oncogene and
its deregulated expression can lead to under- or over-
replication, DNA damage and genetic instability (18).
In mammalian cells, Cdc6 expression peaks during the
G1/S transition and is transcriptionally regulated in a
cell-cycle- and E2F-dependent manner (20–22). Given
AR’s presumptive role as a licensing factor for DNA repli-
cation, it has been proposed that Cdc6 and possibly
other replication factors might be regulatory targets for
AR-signaling pathways (13). Interestingly, when synchro-
nized prostate cancer LNCaP cells are treated with the
antiandrogenic compound bicalutamide (Casodex), the
cells fail to enter S phase and concomitantly downregulate
Cdc6 mRNA expression (23). Furthermore, AR binds at
the human Cdc6 promoter in vivo and androgens were
found to regulate Cdc6 gene expression in AR-positive
prostate cancer cells and xenografts (24,25).
In this study, we investigated whether AR targets
the human Cdc6 gene for transcriptional regulation in
prostate cancer cells in a cell-cycle-dependent manner.
Using androgen-sensitive LNCaP cells, we found that
Cdc6 mRNA and protein expression is activated or
repressed in the presence of androgen or antiandrogen,
respectively. We identiﬁed a 15bp palindromic ARE in
the Cdc6 promoter ( 734bp upstream of the transcription
start site) and show that AR occupies this site in vitro
and in vivo. Mutagenesis of the ARE abolishes AR binding
as well as androgen-dependent Cdc6 transcription.
Intriguingly, and consistent with its presumptive role as a
DNA replication licensing factor, we show that peak occu-
pancy of AR at the Cdc6 promoter occurs during the G1/S
phaseofthecellcycle,concomitantwithpeakCdc6mRNA
expression. Silencing AR expression markedly decreases
both Cdc6 expression and androgen-dependent cellular
proliferation. Signiﬁcantly, we also identiﬁed several
speciﬁc coactivators and corepressors involved in AR-
dependent Cdc6 transcriptional regulation and further
characterized androgen- and antiandrogen-induced altera-
tions in histone H3 acetylation and methylation patterns
at the Cdc6 promoter. Collectively, our results suggest
that Cdc6 is a key regulatory target gene in androgen-
responsive prostate cells and may have important implica-
tions for prostate cancer cell growth and proliferation.
MATERIALS AND METHODS
Cell culture
LNCaP, DU145 and PC3 cells were obtained from the
American Type Culture Collection (Manassas, VA).
1532T-f:AR cells were generated and cultured as described
previously (26). LNCaP cells were routinely maintained in
RPMI 1640 (Invitrogen, Carlsbad, CA) with 10% fetal
bovine serum (FBS; Gemini Bioproducts) along with
penicillin and streptomycin (Invitrogen). DU145 and
PC3 cells were grown in DMEM with 10% FBS and peni-
cillin/streptomycin. In the androgen starvation experi-
ments, cells were grown in phenol red-free medium
containing charcoal/dextran-stripped FBS (CDS–FBS,
Gemini Bioproducts). All cells were maintained in a humi-
diﬁed incubator at 378C and 5% CO2.
Antibodies and reagents
Speciﬁc antibodies against Cdc6, AR, MED1, MED6,
MED14, MED17, SRC1, SRC3, NCoR, SMRT,
HDAC1, HDAC2, HDAC3 and a-tubulin were all from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
against H3R17-2me, H3K4-2me and unmodiﬁed Histone
3 were from Abcam (Cambridge, MA) and antibodies
against acetylated-H3 and H3K9-3me were from
Millipore/Upstate Biotech (Billerica, MA). Horseradish
peroxidase-conjugated anti-rabbit IgG and anti-mouse
IgG were from Cell Signaling (Beverly, MA). Enhanced
Chemiluminescence (ECL) reagents were from Amersham
Pharmacia/GE Healthcare (Piscataway, NJ). The
Luciferase Assay kit was from Promega (Madison, WI)
and the dihydrotestosterone (DHT), nocodazole and
R1881 were all from Sigma (St Louis, MO). Casodex
(Bicalutamide) was generously provided by AstraZeneca
(United Kingdom).
RT–PCR analysis
Total RNA was extracted from prostate cancer cell lines
using TRIzol reagent (Invitrogen). One microgram of
total RNA was incubated with reverse transcriptase
(Invitrogen) and 200mM deoxynucleoside triphosphates
(dNTPs) to generate ﬁrst-strand cDNA and then ampliﬁed
by PCR using Fast Start Taq polymerase (Roche) with
primers speciﬁc for either Cdc6 (24) or -actin (27) for
25 cycles. The PCR products were then analyzed on
1.5% agarose gel stained with ethidium bromide.
Real-time PCR
PCR was performed using the OpticonContinuous
Fluorescence Detection System (MJ Research) using a
SYBR Green PCR kit (Invitrogen). Human b-actin
was used as an internalcontrol for real time RT–PCR
analyses. Non-speciﬁc rabbit IgG was used as an internal
control for real time ChIP.
ChIP analyses
LNCaP cells were cultured in CDS–FBS containing media
for 3days and then treated with DHT (10nM) for 4h.
For the Casodex treatment, LNCaP cells were cultured
in 10% FBS RPMI media and then treated with
Casodex (30mM) for 2h. Antibodies speciﬁc for AR, coac-
tivators, corepressors and covalently modiﬁed histones
were then used to immunoprecipitate formaldehyde
cross-linked chromatin–protein complexes as outlined in
detail (28,29). The immunoprecipitated DNA was then
analyzed via semi-quantitative and real time PCR using
primers spanning the Cdc6 promoter region: Primer set A:
forward, 50-gaa acc cta gtg ttt cgc cat aaa ag-30 ( 825bp),
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( 604bp); Primer set B: forward, 50-gcc ttc acg aaa tgt
act cca c-30 ( 1394bp), and reverse, 50-caa cta gta agt
gga aga gct ag-30 ( 1254bp); Primer set C: forward,
50-gct ctc tca ttg gct gta act c-30 ( 149bp), and reverse,
50-cgc tcg cgc caa atc cga atg-30 (+5bp); Primer set D:
forward, 50-gag act ata act cta cag att g-30 (+14976bp),
and reverse, 50-ctt gaa aca agt ggc ttc atc-30 (+15152bp).
All ChIP experiments were carried out at least three
times. Image processing and quantitation of the semi-
quantitative PCR data was performed using the Quantity
One software (Bio-Rad) (Supplementary Figure S1).
Plasmids
The pGL3-Cdc6-1.7-kb promoter-Luc plasmid was pro-
vided by Dr Joseph Nevins (Duke) and has been described
previously (20). The pSG5-AR construct was provided by
Dr Frank Claessens (Katholieke Universiteit Leuven), the
pRSV-TRb vector was from Dr Herb Samuels (NYU) and
the pCMV-GR construct was from Dr Michael Garabe-
dian (NYU). The pGL2-Cdc6-ARE construct was gener-
ated by PCR by amplifying the Cdc6 promoter region
containing the putative ARE and GATA sites (bps  781
to  575) using primers (forward) 50-ggg gta ccc ata att ccc
tcc cca tga tgt gtg g-30 and (reverse) 50-gaa gat ctc tcc tga
tgg ctg aac tag tga ttt tta tgg-30 and then subcloning the
ampliﬁed fragment into pGL2-Basic (Promega, Madison,
WI). The pGL2-Cdc6-AREmt construct was created via
PCR-generated mutagenesis of the pGL2-Cdc6-ARE con-
struct as described (30) using primers (forward) 50-gaa gat
gca caA GGc ata ata ttc tta ggt tg-30 and (reverse) 50-cct
aag aat att atg CCT tgt gca tct tc-30. The pGL2-Cdc6-
GATA-mt.1 and pGL2-Cdc6-GATA-mt.2 constructs
were generated via PCR-generated mutagenesis using
primers (forward) 50-gca caa atc aag act tac tat gat gaa
gc-3 and (reverse) 50-gct tca tca tag taa gtc ttg att tgt gc-30
for mutant 1 and primers (forward) 50-gca caa atc aag aac
cac tat gat gaa gc-30 and (reverse) 50-gct tca tca tag tgg ttc
ttg att tgt gc-30 for mutant 2.
Luciferase reporter gene assays
LNCaP cells were cultured in CDS–FBS containing media
for 3days and then seeded (1 10
5cells) in 12-well plates
and transfectedwith 100ng pGL3-Cdc6-1.7kb or empty
pGL3 control using Lipofectamine PLUS reagent
(Invitrogen, Carlsbad, CA). In separate experiments,
500ng of either pGL2-Cdc6-ARE, pGL2-Cdc6-AREmt,
pGL2-Cdc6-GATA-mt.1, pGL2-Cdc6-GATA-mt.2, or
empty pGL2 control were transfected via Lipofectamine
PLUS reagent. Three hours post-transfection, the med-
iumwas replaced with fresh media containing or lacking
R1881 (10nM ﬁnal) for an additional 24h. For experi-
ments involving addition of Casodex, cells were grown
in normal FBS prior to transfection. DU145 cells grown
in normal 10% FBS were seeded (1 10
5 cells) in 12-well
plates and cotransfected with 500ng of pGL2-Cdc6-ARE
and 500ng of either pSG5-AR, pCMV-GR, pRSV-TRb,
or their corresponding empty vectors via Lipofectamine
2000 reagent (Invitrogen, Carlsbad, CA). Three hours
post-transfection, the mediumwas replaced with fresh
media containing or lacking R1881 (10nM), Dexametha-
sone (10nM ﬁnal), or T3 (100nM) for an additional 24h.
Cellswere harvested and equivalent amounts of protein
were assayed for luciferase activity using an assay kit
(Promega) and a luminometer. Luciferasevalues were
normalized by using a b-galactosidase (pSV-ßgal)
(Promega) expression vector as internal control.
Electromobility shift assay
The wild-type Cdc6 promoter ARE oligo 50GAA GAT
GCA CAG AAC ATA ATA TTC TTA GGT TG30 and
its complementary strand were annealed generating a
double-stranded template with protruding BglII ends.
Similarly, the mutant ARE oligo 50GGT AAG AAG
ATG CAC AAT ATT CTT AGG TTG30 and its comple-
ment were annealed generating a double-stranded tem-
plate with protruding BglII ends. As a positive control,
a double-stranded MMTV long terminal repeat promoter
ARE template was generated as described previously (26).
The double-stranded AREs were labeled by ﬁlling in with
[a-
32P]dATP (50mCi; Amersham Biosciences) and Klenow
enzyme. To purify the full-length AR protein used for
EMSA, FLAG-tagged human AR (f:AR) was immuno-
puriﬁed from a stable 1532T-f:AR cell line using anti-
FLAG M2 antibodies coupled to agarose beads (Sigma)
as described previously (26). Puriﬁed f:AR protein was
incubated for 15min at room temperature in binding
buﬀer containing 10mM Tris–Cl (pH 7.9), 50mM KCl,
1mM dithiothreitol, 10% glycerol, 1mg/ml bovine serum
albumin, 0.5mg of poly (dI-dC), 1mM EDTA, 0.1%
Nonidet P-40 along with 2ng of
32P-labeled double-
stranded ARE probe. The reactions were electrophoresed
in a prerun 5% polyacrylamide gel, 0.5  Tris borate–
EDTA at 100V for 3–4h. The gel was then dried and
autoradiographed.
RNA interference
AR siRNA was generated using the Silencer siRNA
Construction Kit (Ambion) using the speciﬁc target
sequence 50-GAC CTA CCG AGG AGC TTT C-30 as
previously outlined (31). A scrambled non-speciﬁc
siRNA smart pool was from Dharmacon Research, Inc.,
as previously described(27). The AR siRNA (200nM
ﬁnal) was transfected into LNCaP cells using
Lipofectamine with Plus reagent.
Cell proliferation assay
LNCaP cells were androgen-starved in RPMI media
containing 10% CDS–FBS for 48h and then seeded
(1 10
5cells) in 12-well plates and transfected with AR
siRNA or a non-speciﬁc control siRNA (200nM ﬁnal).
Forty-eight hours post-transfection, the cells were trypsin-
ized and seeded (5 10
4) in 12-well plates and allowed
to proliferate for an additional 48h in CDS–FBS with
or without 10nM DHT or 30mM Casodex. Cell prolifer-
ation was measured by manually counting cell numbers.
Experiments were performed in quadruplicate.
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LNCaP cells cultured in normal serum were seeded 5 10
5
cells per 6-well plate and then transfected with AR siRNA
or a non-speciﬁc control siRNA (200nM ﬁnal). The
cells were either arrested at the borderof G1/S using
the double-thymidine-blockmethodology as described
previously (32) or arrested in G2/M by treating the cells
with 100ng/ml nocodazole for 18h. Then cells were then
harvested for RT–PCR, immunoblot or ChIP analyses as
described above. Synchronization was veriﬁed by ﬁxing
and staining the cells with propidium iodide (20mg/ml)
and then analyzing themusing a Cytomics FC500 ﬂow
cytometer (Beckman Coulter Inc.).
RESULTS
Cdc6 expression in LNCaP cells is modulated in an
androgen- and antiandrogen-dependent fashion
Several previous studies indirectly link AR-signaling path-
ways with Cdc6 expression in androgen-sensitive prostate
cancer cells. For example, when AR-expressing prostate
cancer LNCaP cells are synchronized in the G0/G1 phase
of the cell cycle and then treated with the antiandrogenic
compound Casodex, the cells fail to enter S phase and
concomitantly downregulate Cdc6 mRNA expression
(23). Similarly, a signiﬁcant loss of transcription eﬃciency
of a human Cdc6 promoter-reporter gene was noted in
AR-negative prostate cancer cells as compared with that
observed in AR-positive prostate cells (24). Moreover,
previous LNCaP gene array studies have shown that
Cdc6 mRNA expression increases in the presence of
androgen (33) and decreases in the presence of the anti-
androgen (23). Indeed, we performed human gene micro-
array analyses with androgen-sensitive LNCaP cells
and also identiﬁed Cdc6 as an androgen-responsive gene
(data not shown).
In an eﬀort to validate our microarray data linking
androgen stimulation with Cdc6 expression, RNA was
extracted from LNCaP cells treated with either androgen
(dihydrotestosterone or DHT) or antiandrogen (Casodex)
and then analyzed by RT–PCR using primers speciﬁc for
the Cdc6 gene. As shown in Figure 1A and B, and in
agreement with the previous microarray studies, Cdc6
mRNA increased in a DHT dose-dependent manner
as much as 3-fold, whereas Cdc6 mRNA decreased in
the presence of increasing concentrations of Casodex as
much as 5-fold. Immunoblot analyses showed that DHT-
or Casodex-induced increases or decreases in Cdc6
mRNA were accompanied by a corresponding increase
or decrease in protein expression (Figure 1C and D). By
contrast, when AR-negative DU145 prostate cancer cells
were treated with either DHT or Casodex, no signiﬁcant
increase or decrease in Cdc6 mRNA levels was detected
(Figure 1E and F). Taken together, our ﬁndings show that
androgens and antiandrogens modulate Cdc6 mRNA and
protein expression in androgen-sensitive prostate cancer
cells, but not in prostate cancer cells lacking AR
expression.
Identification of an AR-binding site in the Cdc6 promoter
In view of the importance of Cdc6 in regulating eukaryotic
DNA replication, we were interested in determining
whether AR directly targets the Cdc6 gene for transcrip-
tional regulation. Interestingly, a search of the Cdc6
promoter region for potential AR-binding sites revealed
the presence of a canonical class I steroid hormone
response element (AGAACAnnnTATTCT) (34) spanning
positions  734 to  720-bp upstream of the transcription
start site (Figure 2A). It has been reported that binding
sites for the GATA and ETS families of transcription
factors are enriched proximal to cognate AR-binding
sites in the genome and may play cooperative roles in
mediating an androgen response (3,5,35). Notably, a
GATA element was detected in the Cdc6 gene promoter
just downstream of the putative ARE at position  656bp
and three ETS-binding sites were found at positions  355,
 326 and  211bp (Figure 2A). To determine whether
endogenously expressed AR in LNCaP cells directly
associates with the Cdc6 promoter at or near to the puta-
tive ARE region in vivo, we performed chromatin-
immunoprecipitation (ChIP) assays using an anti-AR
antibody and PCR primer sets corresponding to diﬀerent
regions of the Cdc6 promoter (Figure 2B). Utilizing
LNCaP cells cultured in normal serum, we detected AR
occupancy at the Cdc6 gene-promoter region containing
the putative ARE, but not at an upstream-promoter
region, nor at a downstream region containing the
E2F-binding elements (Figure 2C). Identical results were
observed when ChIP was performed using prostate cancer
1532T cells stably transfected with ectopic FLAG-tagged
AR (1532T-f:AR) (26) (Figure 2C).
We next tested whether recombinant AR can speciﬁ-
cally bind to the Cdc6 ARE in vitro by performing DNA
electromobility shift assays. Accordingly, full-length
human FLAG-AR (f:AR) was puriﬁed from 1532T-
f:AR cells as described (26) and then incubated with a
radiolabeled Cdc6 ARE. A mutated Cdc6 ARE and a
MMTV long terminal repeat promoter ARE were used
as negative and positive controls, respectively. As shown
in Figure 3A and B, f:AR puriﬁed from DHT-treated
1532T-f:AR cells bound eﬃciently with the wild-type
Cdc6 ARE but not with mutated Cdc6 ARE, whereas
f:AR puriﬁed from androgen-starved cells bound only
weakly to the wild-type Cdc6 ARE. Addition of an
anti-AR antibody conﬁrmed the presence of AR in
the protein–DNA complex and as previously reported,
dramatically enhanced the AR:ARE interaction (36)
(Figure 3C). The binding speciﬁcity of f:AR for the
Cdc6 ARE was conﬁrmed by the ability of a molar
excess of unlabeled wild-type ARE to compete for and
inhibit binding with the radiolabeled ARE (Figure 3D).
To conﬁrm that endogenously expressed AR from pros-
tate cancer cells directly binds to the Cdc6 ARE in vitro,
we performed DNA electromobility assays using nuclear
extract prepared from either AR-positive LNCaP cells or
AR-negative PC3 cells. As expected, LNCaP nuclear
extract exhibited strong Cdc6 ARE-binding activity,
whereas no binding activity was observed with the PC3
nuclear extract (Figure 3E). In sum, these results show
Nucleic Acids Research, 2009,Vol.37, No. 14 4829that AR directly binds to ARE in the Cdc6 gene
promoter.
The Cdc6 promoter ARE confers androgen-dependent
transcriptional activation
We next sought to determine whether the ARE in the
Cdc6 gene promoter is responsible for the androgen-
induced increase in Cdc6 mRNA observed in androgen-
sensitive prostate cancer cells (Figure 1). To address this
question, we ﬁrst measured transcription from a Cdc6
promoter-luciferase reporter gene (pGL3-Cdc6-1.7kb)
containing 1.7kb of the native human Cdc6 promoter
region ( 1700 to +7) (20). Androgen-starved LNCaP
cells were transfected with either pGL3-Cdc6-1.7kb or
an empty pGL3 control and then cultured with or without
the synthetic androgen R1881 (Figure 4B). Basal expres-
sion from the pGL3-Cdc6-1.7kb construct (minus R1881)
was considerably higher than that observed with the pGL3
control, presumably due to the presence of Sp1 and E2F
sites in the Cdc6 promoter construct near the transcription
start site. Consistent with the idea that the ARE region
is required for androgen-dependent Cdc6 transcrip-
tion, addition of R1881 stimulated transcription from
pGL3-Cdc6-1.7kb greater than 2-fold (Figure 4B),
whereas addition of the antiandrogen Casodex reduced
transcription by nearly 2-fold (Figure 4C). Moreover,
androgen-dependent transcription from a Cdc6 promoter
reporter construct (pGL2-Cdc6-ARE) containing only the
ARE and GATA region (bps  781 to  575) was stimu-
lated nearly 4-fold in LNCaP cells (Figure 4D) and in
prostate cancer DU145 cells transiently transfected with
AR (Figure 4E).
Given that the Cdc6 ARE comprises a consensus class I
steroid hormone response element, we next asked whether
the element might confer other steroid hormone responses.
Consistent with this notion, transient overexpression of
0
2.5
5
0
2
4
6
0
1
2
3
4
0         1 5       10      30 μM Casodex
Cdc6
β-actin
Cdc6
β-actin
0          1  10       100     nM DHT B A
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
0        5  10       30 μM Casodex
0
2
4
6
0          1         10        100  nM DHT D C
Cdc6
α-tubulin
Cdc6
α-tubulin
P
r
o
t
e
i
n
 
E
x
p
r
e
s
s
i
o
n
P
r
o
t
e
i
n
 
E
x
p
r
e
s
s
i
o
n
0            5     10         30 μM Casodex F E 0          1   10       100  nM DHT
Cdc6
β-actin
Cdc6
β-actin
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
0
0.5
1
1.5
2
0
0.5
1
1.5
2
Figure 1. Cdc6 expression in androgen-sensitive prostate cancer cells is modulated in an androgen- and antiandrogen-dependent manner. (A and C)
LNCaP cells were androgen-starved for 72h and then treated with diﬀerent concentrations of DHT 8h. (B and D) Androgen-starved LNCaP cells
were ﬁrst cultured in CDS–FBS media with 10nM R1881 for 24h to elevate basal Cdc6 expression, and then were treated with diﬀerent concentra-
tions of Casodex for 8h. Total RNA was analyzed by RT–PCR using primers speciﬁc for Cdc6 and -actin (A and B). Bar graph represents results
as the mean S.E. of triplicate reactions. Twenty-ﬁve micrograms of whole cell extract was probed by immunoblot with anti-Cdc6 and anti-tubulin
antibodies (C and D). (E and F) DU145 cells were androgen-starved for 3days and then treated with diﬀerent concentrations of DHT and Casodex
for 8h. Total RNA was analyzed by RT–PCR using primers speciﬁc for Cdc6 and -actin as outlined above.
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transcription from the pGL2-Cdc6-ARE reporter greater
than 2-fold (Figure 4F), yet overexpression of the class II
thyroid hormone receptor elicited no response in the pres-
ence of its cognate ligand (Figure 4G). To further examine
whether the Cdc6 ARE region is directly responsible
for the observed androgen-induced transcription, we car-
ried out site-directed mutagenesis of the putative ARE
(AGAACA!AAGCCA) within the context of the
pGL2-Cdc6-ARE reporter construct (see ‘Materials and
Methods’ section). As expected, mutation of the Cdc6
ARE signiﬁcantly decreased R1881-induced transcription
(Figure 4D). In contrast, two diﬀerent site-directed muta-
tions of the putative GATA site (mutant 1: AGATA
!ACTTA and mutant 2: AGATA!AACCA) within
the context of the pGL2-Cdc6-ARE reporter had only
a modest inhibitory eﬀect on R1881-stimulated tran-
scription (Figure 4D). In summary, our data demonstrate
that the novel ARE located within Cdc6 promoter
( 734bp to  720bp) is functionally required for
androgen-dependent Cdc6 gene expression, whereas a
functional role for the downstream GATA site remains
unclear (see ‘Discussion’ section).
Androgen- and antiandrogen-induced coregulator
recruitment and covalent histone modifications at
the Cdc6 gene promoter in prostate cancer cells
Our ﬁndings showing that androgens and antiandrogens
modulate Cdc6 transcription, and that AR directly binds
at a novel ARE in the Cdc6 gene promoter, strongly sug-
gest that AR targets the Cdc6 gene for transcriptional
regulation. Importantly, AR transcriptional activity in
prostate cells is critically dependent on its interaction
with accessory coregulatory factors and enzymes, and its
subsequent recruitment of these cofactors to its respective
target genes (6,7). To better understand how AR regulates
Cdc6 gene expression, we performed ChIP assays with
LNCaP cells treated with androgen (DHT) or antiandro-
gen (Casodex) using both semi-quantitative and real time
PCR with primers spanning the ARE in Cdc6 promoter
(Figure 5A). Of note, anti-AR antibodies revealed strong
ligand-dependent AR occupancy at the Cdc6 ARE in the
presence of both DHT and Casodex (Figure 5B, C and E).
In order to identify speciﬁc cofactors recruited by AR to
the Cdc6 promoter, antibodies against known NR tran-
scriptional coactivators and corepressors were utilized.
Furthermore, antibodies speciﬁc for acetylated or methyl-
ated histone H3 were employed to identify androgen- and
antiandrogen-induced alterations in histone modiﬁcations
at the Cdc6 promoter.
Mediator is a conserved transcriptional coregulatory
complex that plays a vital role in nuclear hormone recep-
tor (NR)-regulated gene expression (8,9). The complex
binds to DNA-bound NRs and promotes the assembly
and activation of RNA pol II and its associated factors
at core promoters and may also play a role in facilitating
the recruitment of histone-modifying enzymes. A single
subunit of the complex termed MED1 targets Mediator
to AR and other NRs in the presence of their cognate
ligand. A recent study found that MED1 was indispens-
able for androgen-dependent transcription of the prostate
speciﬁc antigen (PSA) gene in LNCaP cells and that RNAi
silencing of MED1 was accompanied by a signiﬁcant
reduction in RNA pol II recruitment at the PSA gene
promoter (37). Consistent with these ﬁndings, our lab
recently found that MED1 silencing in LNCaP cells mark-
edly inhibited androgen-dependent cellular proliferation
and progression into the G2/M phase of the cell cycle (38).
Given the importance of MED1-Mediator in prostate
cancer cell proliferation and cell-cycle progression, we ﬁrst
used anti-MED1 antibodies to precipitate formaldehyde
cross-linked chromatin from DHT-stimulated LNCaP
cells. Similar to previous LNCaP ChIP studies at the
PSA gene promoter (28,37), we detected robust andro-
gen-dependent recruitment of MED1 at the Cdc6
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Figure 2. AR binds at the Cdc6 gene in vivo in a promoter region
containing a consensus ARE. (A) DNA sequence of the human Cdc6
promoter region. The ARE is boxed, E2F sites are capitalized and
underlined, the GATA site is capitalized and in italics, and the ETS
sites are underlined. (B) Schematic representation of the human Cdc6
promoter showing relative location of three PCR primer sets (A, B and
C) used for ChIP analyses. (C) Chromatin prepared from LNCaP and
1532T-f:AR cells cultured in normal serum was used for ChIP along
with anti-AR antibodies. Semi-quantitative PCR was performed using
the three primer sets shown in (B).
Nucleic Acids Research, 2009,Vol.37, No. 14 4831promoter (Figure 5B and E). Moreover, the androgen-
dependent binding of other Mediator subunits (MED6,
MED14 and MED17) support the notion that AR recruits
the entire Mediator complex to the Cdc6 gene promoter.
Signiﬁcantly, and consistent with Mediator’s role in facil-
itating the recruitment of RNA pol II (9), we also detected
DHT-induced binding of RNA pol II at the Cdc6 pro-
moter (Figure 5B and E).
Histone acetylation, a process dynamically controlled
by histone acetyltransferases (HATs) and histone deacety-
lases (HDACs), has a profound impact on chromatin
structure and consequently gene transcription (39).
In general, acetylation of lysine residues on histones
H3 and H4 facilitates transcriptional activation
whereas deacetylation reverses this eﬀect. The p160/SRC
family of coactivators interact with NRs in a ligand-
dependent manner and enhance their transcriptional
transactivation (40). Two members of this family,
p160/SRC-1 and p160/SRC-3, possess intrinsic HAT
activity and bind and work together with other more
potent HATs (CBP, p300 and PCAF) to acetylate his-
tones. Interestingly, we detected strong DHT-dependent
recruitment of both p160/SRC-1 and p160/SRC-3 at the
Cdc6 promoter that was concomitantly associated with
ARE:    MMTV  Cdc6 wt    Cdc6 mt.
f:AR(ng):    0     10     0     10    20    0    20
A Cdc6 wt ARE
α-AR IgG:    – – +
f:AR(ng):   0      20     20
C B Cdc6 wt ARE
f: AR:      +        + 
DHT:      – +
D
f:AR: – +
cold ARE (pmols): 0 0 0.2 0.5 1 0 0.2 0.5 1
Cdc6 ARE wt Cdc6 ARE mt.
LnCaP NE (μg) –                     –     –    – 246
E
PC3 NE (μg) 246 –    –   –   –
Cdc6 ARE wt
AR
Figure 3. AR directly binds to the Cdc6 ARE in vitro in the presence of ligand. (A–D) Full-length human FLAG-AR (f:AR) puriﬁed from DHT-
cultured prostate cancer 1532T cells stably expressing ectopic f:AR (26) was incubated with a
32P-radiolabeled Cdc6 ARE and then assayed by
EMSA (see Methods section). A mutated Cdc6 ARE and a MMTV long terminal repeat promoter ARE were used as negative and positive controls,
respectively. In (B), equal amounts of f:AR puriﬁed from either androgen-starved ( DHT) or DHT-treated (+DHT) 1532T-f:AR cells was used. In
(C), anti-AR antibodies were added to the binding reaction as indicated. In (D), a molar excess of cold unlabeled wild-type ARE or mutated ARE
was added to binding reactions as indicated. (E) Nuclear extract prepared from DHT-treated LNCaP or PC3 cells was incubated with the wild-type
32P-radiolabeled Cdc6 ARE and assayed by EMSA as described above.
4832 Nucleic Acids Research, 2009, Vol. 37,No. 14an increase in histone H3 acetylation (Figure 5B, D
and E). By contrast, treatment of LNCaP cells with
the antiandrogen Casodex triggered a pronounced
decrease in histone H3 acetylation and was accom-
panied by the recruitment of HDACs-1, -2 and -3
(Figure 5C). The NR corepressors NCoR and SMRT,
which directly bind to AR in the presence of antiandro-
gens, are thought to recruit HDACs to AR (6,7). Notably
in this regard, we observed strong Casodex-dependent
recruitment of SMRT, but not NCoR, to the Cdc6
promoter (Figure 5C). Although the recruitment of
SMRT is consistent with transcriptional repression (6),
the data contrasts earlier studies showing strong
Casodex-dependent recruitment of both NCoR and
SMRT at the PSA gene (41–43) and suggest that struc-
tural diﬀerences between the PSA and Cdc6 promoter/
enhancer regions diﬀerentially inﬂuence AR–corepressor
complex recruitment and binding.
Histone methylation has emerged as an equally impor-
tant modiﬁcation linked to both transcriptional activa-
tion and repression (39). In particular, methylation of
histone H3-lysine 4 (H3K4) is associated with active
transcription, while methylation of histone H3-lysine 9
(H3K9) is associated with gene silencing and heterochro-
matin formation (44). Furthermore, methylation of
histone H3 arginine residues (R2, R17 and R26) are
covalent modiﬁcations associated with ligand-dependent
transcriptional activation by NRs (45). Strikingly, we
observed a marked DHT-dependent decrease in H3K9
tri-methylation at the Cdc6 promoter as well as a
modest increase in H3R17 di-methylation (Figure 5D
and E), both marks consistent with Cdc6 transcriptional
activation. By contrast, we failed to observe any signiﬁ-
cant increase in H3K4 methylation following addition of
DHT. Collectively, these ﬁndings suggest that in addition
to Mediator and HAT-containing coactivators, andro-
gen-bound AR may also recruit H3K9-demethylase and
H3-arginine-methyltransferase activities to the Cdc6 pro-
moter (see ‘Discussion’ section). Conversely, antiandro-
gen-bound AR recruits SMRT–HDAC complexes that
deacetylate histones at the Cdc6 promoter and facilitate
gene silencing.
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expression in prostate cancer cells
AR is thought to act as a master regulator of G1-S phase
progression in androgen-dependent prostate cancer cells
(12). In most of the immortalized mammalian cell lines
tested thus far, Cdc6 mRNA expression peaks during
the G1/S phase (20–22). In view of our data showing
that AR binds at Cdc6 promoter and regulates transcrip-
tion in a ligand-dependent manner, we investigated
whether AR is involved in regulating cell-cycle-dependent
Cdc6 mRNA expression in prostate cancer cells. LNCaP
cells grown in normal serum were ﬁrst transfected with
AR siRNA or a non-speciﬁc control siRNA and then
synchronized in G1/S via thymidine block or in G2/M
via nocodazole treatment (see ‘Materials and Methods’
section). Synchronization was conﬁrmed by ﬂow cytome-
try and untreated (unsynchronized) cells were used as
controls (Figure 6A).
Similar to previous ﬁndings, we observed that Cdc6
mRNA levels in LNCaP cells are higher at G1/S than at
G2/M (Figure 6C and D, left panels). AR protein levels
also peak at G1/S relative to G2/M (Figure 6B, left panels)
and when ChIP assays were performed using synchronized
LNCaP cells, we detected a markedly higher occupancy
of AR at the Cdc6 gene promoter at G1/S relative to
G2/M (Figure 6E, left panels). Interestingly, when
LNCaP cells were transfected with AR siRNA, there
was a notable decrease in Cdc6 mRNA levels at G1/S
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4834 Nucleic Acids Research, 2009, Vol. 37,No. 14(Figure 6C and D, right panels) that was accompanied by
a sharp loss of AR occupancy at the Cdc6 promoter as
determined by ChIP (Figure 6E, right panels). These ﬁnd-
ings correlate elevated AR protein expression and occu-
pancy at the Cdc6 gene at G1/S phase with elevated levels
of Cdc6 mRNA at G1/S, and consistent with its presump-
tive role as a licensing factor for the onset of S phase,
suggest that AR promotes cell-cycle-dependent expression
of Cdc6 mRNA.
AR silencing inhibits Cdc6 expression and cell-cycle
progression
Given the importance of Cdc6 in regulating DNA replica-
tion, we asked whether loss of AR-mediated Cdc6 expres-
sion negatively eﬀects androgen-dependent prostate
cancer cell proliferation. Toward that end, equal numbers
of androgen-starved LNCaP cells were transfected with
AR siRNA or a non-speciﬁc control siRNA and then
cultured with or without DHT for 2days. In agreement
with our earlier results, AR silencing concomitantly inhi-
bits Cdc6 expression (Figure 7A) and in turn, dramatically
decreases androgen-dependent cellular proliferation
(Figure 7B). Indeed, loss of AR decreased the average
DHT-induced LNCaP cell number by 61%, and consis-
tent with a critical requirement for Cdc6 at the onset of
S phase, loss of AR triggers cell-cycle arrest in the G0
and G1 phases (Figure 7D). Interestingly, we have also
found that silencing of MED1, a key AR coactivator
for Cdc6 transcription, likewise inhibited Cdc6 expression,
decreased androgen-dependent proliferation, and trig-
gered cell-cycle arrest in G1 phase (38). These results sup-
port the notion that AR and its associated coregulatory
factors play an important role in licensing DNA replica-
tion by regulating the expression of Cdc6 and possibly
other key replication factors.
DISCUSSION
In eukaryotic cells, Cdc6 plays a crucial functional role
late in G1 phase by regulating the formation of pre-
replication complexes that allow for the initiation of
DNA synthesis at S phase. Indeed, whether or not Cdc6
is loaded on chromatin at the origins of DNA replication
is believed to distinguish between cells that will continue
through G1 to S phase versus those that will enter quies-
cence (17). Given its functional importance, Cdc6 expres-
sion is tightly regulated at the level of transcription,
protein phosphorylation, and protein turnover (18,19).
In mammalian cells, Cdc6 gene expression peaks at G1/S
and is dependent on the presence of two E2F-binding sites
in the proximal promoter which have been shown to
confer both positive and negative transcriptional
responses (20,21). G1 cyclins and cyclin dependent kinases
have been proposed to activate promoter-bound E2F in
mid to late G1 via the phosphorylation and displacement
of inhibitory retinoblastoma (Rb) proteins (22).
Mallik et al. (25) ﬁrst demonstrated the importance of
an ARE in the Cdc6 promoter using luciferase assays,
mutagenesis and ChIP in prostate cancer xenografts and
cell lines. The study presented here extends this previous
work with two important ﬁndings. First, we show for the
ﬁrst time that Cdc6 expression is under the regulatory
control of AR in a cell-cycle dependent manner. Given
the functional importance of Cdc6 in DNA replication,
our results implicate the Cdc6 gene as a key regulatory
target in AR-signaling pathways and provide new insights
into AR’s presumptive role as a master regulator of G1-S
phase progression. Indeed, given that AR-signaling
pathways become aberrantly hyperactivated in neoplastic
prostate cells (10), it is conceivable that deregulated
B
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Figure 6. AR promotes cell-cycle-dependent Cdc6 mRNA expression in
prostate cancer cells. LNCaP cells cultured in normal serum were ﬁrst
transfected with AR siRNA or a non-speciﬁc control siRNA (200nM
ﬁnal) and then synchronized in the G1/S phase via thymidine block or
in the G2/M phase via nocodazole treatment. Untreated (unsynchro-
nized) cells were used as controls. Cell-cycle distribution of the syn-
chronized LNCaP cells was determined by ﬂow cytometry. (A) The
mean average of the percentage of cells in the sub-G0, G1/S and
G2/M phases of the cell cycle from three separate synchronization
experiments is shown. (B) Whole-cell extract was prepared and equiv-
alent amounts of protein were probed by immunoblot using anti-AR or
anti-a-tubulin antibodies. (C) Total RNA was analyzed by RT–PCR
using primers speciﬁc for Cdc6 and -actin.( D) RNA samples from
(C) were analyzed using real-time PCR. Bar graph represents results as
the mean SE of triplicate assays. (E) ChIP was were carried out as
described in Figure 6 using PCR primer set A. Non-speciﬁc rabbit IgG
was used as a negative control.
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growth and progression. Secondly, we have identiﬁed
several speciﬁc coactivators and corepressors involved
in AR-dependent Cdc6 transcriptional regulation and
have further characterized androgen- and antiandrogen-
induced alterations in histone H3 acetylation and methyl-
ation patterns at the Cdc6 promoter. Thus, the
ﬁndings here have important implications for the funda-
mental molecular mechanisms used by AR to regulate
transcription.
Considering the fact that other steroid NRs (e.g. the
progesterone and glucocorticoid receptors) are potent
regulators of cellular proliferation and G1-S phase pro-
gression (46), it is interesting to note that the ARE found
in the Cdc6 promoter (AGAACAnnnTATTCT) constitu-
tes a near perfect class I steroid hormone response element
(34). Thus, other NRs in unrelated steroid hormone-
responsive tissues might also target Cdc6 for transcrip-
tional regulation. Consistent with this notion, we observed
a modest yet reproducible ligand-dependent activation of
a Cdc6-ARE reporter gene via the glucocorticoid receptor
(Figure 4F). Binding sites for the GATA and ETS families
of transcription factors have been identiﬁed proximal to
AREs in the genome (35) and both types of factors have
been proposed to facilitate AR binding to the ARE (3).
Interestingly, both GATA and ETS-binding sites were
detected in the Cdc6 gene promoter just downstream of
the ARE (Figure 2A). Although we were unable to discern
a functional requirement for either factor in the studies
here, it remains plausible that GATA and/or ETS factors
cooperate with AR in mediating the Cdc6 androgen
response in vivo.
Signiﬁcantly, we identiﬁed several of the transcriptional
coregulatory factors involved in AR-dependent transcrip-
tional regulation of the Cdc6 gene and further character-
ized androgen- and antiandrogen-induced alterations in
histone H3 acetylation and methylation patterns at the
Cdc6 promoter. Our ﬁndings show that in the presence
of androgens, AR recruits Mediator and p160/SRC-HAT
complexes to the Cdc6 promoter, which in turn facilitate
histone acetylation at the promoter region and the recruit-
ment of RNA pol II. Contrarily, in the presence of anti-
androgens, AR recruits SMRT–HDAC complexes to the
Cdc6 promoter that in turn facilitate histone deacetylation.
We also observed a pronounced androgen-dependent
decrease in H3K9 tri-methylation at the Cdc6 promoter
as well as a modest increase in H3R17 di-methylation,
both marks consistent with transcriptional activation
(39). These ﬁndings suggest that in addition to the afore-
mentioned coactivators, androgen-bound AR also recruits
the histone H3-arginine methyltransferase CARM1 (which
speciﬁcally facilitates H3R17 methylation) (47) and the
histone H3-lysine demethylase JMJD2C (which speciﬁ-
cally demethylates H3K9-3me) (48). Importantly, both
CARM1 and JMJD2C have been previously shown to
associate with AR and enhance AR-dependent transcrip-
tion (41,47,49).
In agreement with our ﬁndings showing that AR silenc-
ing in LNCaP cells decreases Cdc6 expression, inhibits
androgen-induced cell growth and triggers G0 and G1
cell-cycle arrest (Figure 7), we have likewise found that
MED1 silencing in LNCaP cells also inhibits Cdc6 expres-
sion and decreases androgen-dependent progression into
G2/M phase (38). These data, together with the ChIP
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Figure 7. AR silencing inhibits Cdc6 expression and cell-cycle progression. (A) Whole cell extract prepared from LNCaP cells transfected with AR
siRNA or a non-speciﬁc control siRNA (200nM ﬁnal) was probed by immunoblot with antibodies against AR, Cdc6 or a-tubulin. Equal numbers of
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4836 Nucleic Acids Research, 2009, Vol. 37,No. 14ﬁndings discussed above, suggest that MED1-Mediator
plays a particularly important coactivator role in
AR-dependent transcriptional activation of Cdc6.
Indeed, MED1 is indispensable for AR-dependent tran-
scription of the PSA gene in LNCaP cells and MED1
silencing was accompanied by a signiﬁcant reduction in
RNA pol II recruitment at the PSA gene promoter (37).
Thus in addition to the covalent histone modiﬁcations and
chromatin remodeling events fulﬁlled by other types
of AR coactivators, MED1-Mediator likely plays a rate-
limiting role in facilitating the assembly and activation
of RNA pol II and its associated factors at Cdc6 and
other AR target genes.
A ﬂow cytometry approach was recently utilized to
show that AR is degraded at the M phase of each cell
cycle in diﬀerent prostate cancer cell lines thus suggesting
that mitotic AR degradation may be a requirement to
license a new round of DNA replication (13). Consistent
with a presumptive role as a DNA replication-licensing
factor, we found that AR levels in LNCaP cells were
signiﬁcantly higher at G1/S than at G2/M (Figure 6).
Furthermore, we found that peak occupancy of AR at
the Cdc6 promoter occurs during the G1/S phase of the
cell cycle, concomitant with peak Cdc6 mRNA expression,
and when LNCaP cells were transfected with AR siRNA,
there was notable decrease in Cdc6 mRNA levels at G1/S.
These ﬁndings suggest that AR cooperates with E2F to
promote cell-cycle-dependent Cdc6 gene expression.
Interestingly, it has been reported that AR can directly
interact with Rb proteins (50,51). Thus, in addition
to the transactivation mechanisms outlined above, AR
might also form complexes with Rb at the Cdc6 promoter
that alleviate inhibitory constraints on promoter-bound
E2F factors (25). In sum, our results suggest that Cdc6
is a key-regulatory target gene in androgen-sensitive pros-
tate cells and help clarify the molecular role of AR during
G1-S phase progression of the mammalian cell cycle.
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